SEC Company Response from Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443) (MIST) — May 6, 2019
Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443)
Date: May 6, 2019 · CIK: 0001408443 · Accession: 0001104659-19-027188
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230846
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Re: Milestone Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-230846
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, wish to advise you that approximately 935 copies of the Preliminary Prospectus included in the Registration Statement on Form S-1 were distributed during the period April 29, 2019 through the date hereof, to prospective underwriters, institutions, dealers and others.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
In accordance with Rule 461 of the Act, we hereby join in the request of Milestone Pharmaceuticals Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern time on May 8, 2019, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
Very truly yours,
By:
Show Raw Text
CORRESP 1 filename1.htm Jefferies LLC Cowen and Company, LLC Piper Jaffray & Co. 520 Madison Avenue 599 Lexington Avenue 800 Nicolette Mall New York, NY 10022 New York, New York 10022 Minneapolis, Minnesota 55402 May 6, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Milestone Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-230846 Dear Sir/Madam: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, wish to advise you that approximately 935 copies of the Preliminary Prospectus included in the Registration Statement on Form S-1 were distributed during the period April 29, 2019 through the date hereof, to prospective underwriters, institutions, dealers and others. We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. In accordance with Rule 461 of the Act, we hereby join in the request of Milestone Pharmaceuticals Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern time on May 8, 2019, or as soon thereafter as practicable. [Remainder of page intentionally left blank] Very truly yours, By: JEFFERIES LLC By: /s/ Matthew Kim Name: Matthew Kim Title: Managing Director By: COWEN AND COMPANY, LLC By: /s/ Chris Swindle Name: Chris Swindle Title: Managing Director By: PIPER JAFFRAY & CO. By: /s/ Chad Huber Name: Chad Huber Title: Managing Director [Signature page to Acceleration Request Letter] 2